Peter Neumann in New England Journal of Medicine: Cost-Effectiveness 2.0 -- Poised for a Second Act?
PHE Scientific Advisor Peter Neumann, along with co-author Gillian Sanders, offers a new perspective on cost-effectiveness analysis, just published in the New England Journal of Medicine. Neumann and Sanders provide an overview of recent work, and argue that cost-effectiveness analysis should be an essential part of healthcare decision making.
To read the article, please click here.
In this unique one-hour webinar, Dr. Jena outlines a broader framework for assessing value to improve identification of not only the highest-value treatments, but also low-value therapies on which spending can safely be reduced.